DiscoverNew Retina Radio by EyetubeReal-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR
Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR

Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR

Update: 2024-10-092
Share

Description

Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress—and how do these data inform our understanding of GA? Ted Leng, MD, stopped by the show to share the findings from his research on the natural history of GA, which he recently delivered on the podium in Lisbon. And Michael Klufas, MD, joined us for a discussion about another real-world study. This time, it was a retrospective multicenter outcomes analysis following multiple injections of high-dose aflibercept (Eylea HD, Regeneron) for treatment of wet AMD, DME, and DR. How did treatment-naïve patients fare compared with previously treated patients? And did treatment intervals improve? Stick with us to find out.


New Retina Radio is not affiliated with the official program of Retina Society.

Comments 
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR

Real-World Studies Reported in Lisbon: Untreated GA Progression and High-Dose Aflibercept in Wet AMD, DME, and DR

Retina Today

We and our partners use cookies to personalize your experience, to show you ads based on your interests, and for measurement and analytics purposes. By using our website and our services, you agree to our use of cookies as described in our Cookie Policy.